scholarly article | Q13442814 |
P356 | DOI | 10.1056/NEJM198408233110802 |
P698 | PubMed publication ID | 6749206 |
P50 | author | Alfred D Steinberg | Q117315555 |
P2093 | author name string | Klippel JH | |
Balow JE | |||
Decker JL | |||
Plotz PH | |||
Muenz LR | |||
Joyce KM | |||
Antonovych TT | |||
Austin HA 3rd | |||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lupus nephritis | Q1621830 |
P304 | page(s) | 491-495 | |
P577 | publication date | 1984-08-01 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | Effect of treatment on the evolution of renal abnormalities in lupus nephritis | |
P478 | volume | 311 |
Q69773257 | Analysis of risk factors for patient and renal survival in crescentic glomerulonephritis |
Q33746862 | Anti-DNA autoantibodies and systemic lupus erythematosus |
Q79839545 | Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial |
Q87393398 | Chapter 12: Lupus nephritis |
Q87393403 | Chapter 14: Anti-glomerular basement membrane antibody glomerulonephritis |
Q35579156 | Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation |
Q57011999 | Clinical and prognostic value of serial renal biopsies in lupus nephritis |
Q70031023 | Clinical significance of U1-RNP immune complexes in mixed connective tissue disease and systemic lupus erythematosus |
Q69259494 | Clinical significance of renal biopsies showing mixed mesangial and global proliferative lupus nephritis |
Q34309764 | Combination treatment in autoimmune diseases: systemic lupus erythematosus. |
Q69552546 | Correlation of renal histology with outcome in children with lupus nephritis |
Q77798502 | Current role of renal biopsy in patients with SLE |
Q37949332 | Current treatment recommendations for lupus nephritis |
Q36711562 | Cyclophosphamide toxicity. Characterising and avoiding the problem |
Q35087985 | Dexamethasone induces connective tissue growth factor expression in renal tubular epithelial cells in a mouse strain-specific manner |
Q41226267 | Effect of long-term normalization of serum complement levels on the course of lupus nephritis |
Q54395791 | Effects of cyclosporine in severe systemic lupus erythematosus. |
Q40465520 | Glomerular thrombosis predicts progression of glomerulonephritis: Can we prevent progression? |
Q42479257 | Glucocorticoid enhances hypoxia- and/or transforming growth factor-β-induced plasminogen activator inhibitor-1 production in human proximal renal tubular cells |
Q40883177 | Immunosuppressive drug therapy in lupus nephritis |
Q35547376 | Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide |
Q40828770 | Indications for, and use of, cytotoxic agents in SLE. |
Q64113375 | Innate Immune Cells' Contribution to Systemic Lupus Erythematosus |
Q73407589 | Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus |
Q54352606 | Intermittent intravenous cyclophosphamide therapy for lupus nephritis. |
Q52886016 | Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. |
Q36302245 | Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis |
Q36840240 | Kidney disease in systemic lupus erythematosus |
Q73604873 | Lupus nephritis |
Q40665188 | Lupus nephritis in childhood and adolescence |
Q69420359 | Lupus nephritis. Middlesex, October 20, 1988. Abstracts |
Q67299868 | Lupus nephritis: more answers needed |
Q33614633 | New approaches to treating systemic lupus erythematosus |
Q35039863 | Newer drugs for the treatment of lupus nephritis |
Q35814458 | Outcome of the acute glomerular injury in proliferative lupus nephritis |
Q68145720 | Pemphigus |
Q36748174 | Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data |
Q46839690 | Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group |
Q40506590 | Prognosis in systemic lupus erythematosus |
Q33286668 | Prognostic factors in systemic lupus erythematosus |
Q57945954 | References |
Q68591107 | Renal biopsy |
Q67560104 | Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group |
Q35595464 | Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease |
Q67730594 | Severe recurrent lupus laryngitis |
Q42148555 | Stem cell transplantation: limits and hopes |
Q68862114 | Systemic lupus erythematosus |
Q40506580 | Systemic lupus erythematosus--disease management |
Q38791636 | The treatment of lupus nephritis |
Q34731092 | Therapy of systemic lupus erythematosus: a look into the future |
Q72002018 | Treatment of lupus glomerulonephritis with intravenous cyclophosphamide |
Q37822658 | Treatment of proliferative lupus nephritis: a slowly changing landscape |
Q74022703 | Treatment of systemic lupus erythematosus |
Q36840264 | Treatment of systemic lupus erythematosus: which options do we have for therapy regimens? |
Q34403507 | Treatment of vasculitis |
Q33893383 | Update on cyclophosphamide for systemic lupus erythematosus |
Search more.